Home/Filings/4/0001214659-19-004750
4//SEC Filing

Brister Mark 4

Accession 0001214659-19-004750

CIK 0001427570other

Filed

Jul 24, 8:00 PM ET

Accepted

Jul 25, 4:30 PM ET

Size

5.9 KB

Accession

0001214659-19-004750

Insider Transaction Report

Form 4
Period: 2019-07-23
Brister Mark
VP of Research and Development
Transactions
  • Award

    Stock Option (Right to Buy)

    2019-07-23+35,00035,000 total
    Exercise: $0.96Exp: 2029-07-23Common Stock (35,000 underlying)
Footnotes (2)
  • [F1]Subject to the grantee's continued status as a service provider with the Issuer through the applicable vesting date, the option shall vest as to 100% of the shares underlying the option on the day following the filing date of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, based on the achievement of performance goals on or prior to December 31, 2019.
  • [F2]Share amounts do not reflect the impact of a 1-for-10 reverse stock split that became effective after the grant date for the options referenced herein.

Issuer

OBALON THERAPEUTICS INC

CIK 0001427570

Entity typeother

Related Parties

1
  • filerCIK 0001323223

Filing Metadata

Form type
4
Filed
Jul 24, 8:00 PM ET
Accepted
Jul 25, 4:30 PM ET
Size
5.9 KB